Literature DB >> 20188552

Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).

Hwei-Ru Tsou1, Gloria MacEwan, Gary Birnberg, George Grosu, Matthew G Bursavich, Joel Bard, Natasja Brooijmans, Lourdes Toral-Barza, Irwin Hollander, Tarek S Mansour, Semiramis Ayral-Kaloustian, Ker Yu.   

Abstract

We discovered 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR). Since phenolic OH groups pose metabolic liability, one of the two hydroxyl groups was selectively removed. The SAR data showed the structural features necessary for subnanomolar inhibitory activity against mTOR kinase as well as selectivity over PI3Kalpha. An X-ray co-crystal structure of one inhibitor with the mTOR-related PI3Kgamma revealed the key hydrogen bonding interactions. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20188552     DOI: 10.1016/j.bmcl.2010.01.135

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  9 in total

1.  Analogue-based approaches in anti-cancer compound modelling: the relevance of QSAR models.

Authors:  Mohammed Hussaini Bohari; Hemant Kumar Srivastava; Garikapati Narahari Sastry
Journal:  Org Med Chem Lett       Date:  2011-07-18

2.  A selectivity study on mTOR/PI3Kα inhibitors by homology modeling and 3D-QSAR.

Authors:  Ting Ran; Tao Lu; Haoliang Yuan; Haichun Liu; Jian Wang; Weiwei Zhang; Ying Leng; Guowu Lin; Shulin Zhuang; Yadong Chen
Journal:  J Mol Model       Date:  2011-04-27       Impact factor: 1.810

Review 3.  Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.

Authors:  Yu Liu; Wen-Zhu Wan; Yan Li; Guan-Lian Zhou; Xin-Guang Liu
Journal:  Oncotarget       Date:  2017-01-24

4.  A facile synthesis and anticancer activity of some novel thiazoles carrying 1,3,4-thiadiazole moiety.

Authors:  Sobhi M Gomha; Nabila A Kheder; Mohamad R Abdelaziz; Yahia N Mabkhot; Ahmad M Alhajoj
Journal:  Chem Cent J       Date:  2017-03-21       Impact factor: 4.215

5.  Synthesis of New 3-Heteroarylindoles as Potential Anticancer Agents.

Authors:  Abdou O Abdelhamid; Sobhi M Gomha; Nadia A Abdelriheem; Saher M Kandeel
Journal:  Molecules       Date:  2016-07-16       Impact factor: 4.411

Review 6.  The azaindole framework in the design of kinase inhibitors.

Authors:  Jean-Yves Mérour; Frédéric Buron; Karen Plé; Pascal Bonnet; Sylvain Routier
Journal:  Molecules       Date:  2014-11-28       Impact factor: 4.411

7.  Isovitexin Depresses Osteoarthritis Progression via the Nrf2/NF-κB Pathway: An in vitro Study.

Authors:  Xiaofen Hu; Ruijie Li; Ming Sun; Ying Kong; Haifeng Zhu; Fujiang Wang; Quanqing Wan
Journal:  J Inflamm Res       Date:  2021-04-13

8.  QSAR, molecular docking and ADMET properties in silico studies of novel 4,5,6,7-tetrahydrobenzo[D]-thiazol-2-Yl derivatives derived from dimedone as potent anti-tumor agents through inhibition of C-Met receptor tyrosine kinase.

Authors:  Ossama Daoui; Souad Elkhattabi; Samir Chtita; Rachida Elkhalabi; Hsaine Zgou; Adil Touimi Benjelloun
Journal:  Heliyon       Date:  2021-07-03

9.  S-allyl cysteine reduces osteoarthritis pathology in the tert-butyl hydroperoxide-treated chondrocytes and the destabilization of the medial meniscus model mice via the Nrf2 signaling pathway.

Authors:  Zhenxuan Shao; Zongyou Pan; Jialiang Lin; Qingqian Zhao; Yuqian Wang; Libin Ni; Shiyi Feng; Naifeng Tian; Yaosen Wu; Liaojun Sun; Weiyang Gao; Yifei Zhou; Xiaolei Zhang; Xiangyang Wang
Journal:  Aging (Albany NY)       Date:  2020-10-07       Impact factor: 5.682

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.